Phase I Study of Paclitaxel and Uracil plus Tegafur Combination in Patients with Pretreated Metastatic Breast Cancer: Drug Sequencing Based on Preclinical Modelling Studies

Objective: Taxanes and fluoropyrimidines are active in metastatic breast cancer (MBC), and their combination has proven effective in anthracycline-refractory patients. We conducted a phase I study to determine the maximum tolerated dose (MTD) of uracil plus tegafur (UFT) given in combination with le...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology 2007-01, Vol.72 (1-2), p.118-124
Hauptverfasser:	Passardi, A., Maltoni, R., Milandri, C., Cecconetto, L., Massa, I., Zoli, W., Tesei, A., Fabbri, F., Nanni, O., Amadori, D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cell Line, Tumor Chemotherapy Clinical outcomes Clinical trials Drug Administration Schedule Drug dosages Drug Screening Assays, Antitumor Female Gynecology. Andrology. Obstetrics Humans Laboratory/Clinical Translational Research Leucovorin - administration & dosage Mammary gland diseases Maximum Tolerated Dose Medical sciences Middle Aged Models, Theoretical Neoplasm Metastasis Oncology Paclitaxel - administration & dosage Pharmacology Tegafur - administration & dosage Tumors Uracil - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!